Call +49 6221 8278-0

PROGEN - passion for research

close×

anti-Melanoma-Associated Antigen mouse monoclonal, NKI/C-3, ascites fluid

Recognizes melanoma-associated antigen in melanoma cells and nevocellular nevi. Cross-reaction with carcinoids; no reaction with normal melanocytes or epithelium except for mast cells, histiocytes, bronchial glands.
Cat. No.: 10819
Quantity:  1 mL

Delivery Time: usually 1-7 working days

$293.00
Excl. 19% Tax, excl. Shipping Cost

Call us now for more information on our products: +49 6221 8278-0

Any more questions?
PRODUCT REQUEST

Specifications

Product description

Host mouse
Antibody Type monoclonal
Isotype IgG1
Clone NKI/C-3
Immunogen isolated from human melanoma cells
Purification ascites
Conjugate unconjugated
Formulation contains 0.09% sodium azide
Storage short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/ thaw cycles
Note centrifuge prior to opening
Intended use Research use only
Tested species reactivity human

Applications

Tested applications Tested dilutions
ELISA assay dependent
Immunohistochemistry (IHC) - paraffin 1:5 - 1:10 (microwave treatment recommended)
Western Blot (WB) assay dependent

Background

Details

NKI/C-3 recognizes a melanoma-associated antigen present in the cytoplasm of melanoma cells and nevocellular nevi, in contrast to most mabs against melanoma-associated antigens present in the membrane, which are not retained after formalin fixation. Therefore, the mab is very useful for paraffin sections in routine pathology. Cross reactivity with carcinoids, medullary carcinomas of the thyroid, and occasionally prostatic, primary breast, avarian, and lung carcinomas may be observed.
No reaction is seen with basal cell carcinomas or brain tumors. NKI/C-3 does not react with normal melanocytes or other normal tissues except for mastcells, histiocytes, salivary glands, bronchial glands, pancreatic und prostatic epithelium.
For the diagnosis of melanoma, the antibody should be used in combination with other antibodies (e.g. cytokeratin immunoreactivity indicative for carcinoma versus vimentin immunoreactivity indicative for melanoma).
In immunoblotting the antibody reacts with diffuse protein bands between 25 and 100 kD.
Positive control: Melanoma.

Reference

Material safety data sheet

Please complete the form below to request a material safety data sheet

Personal Info

* Required Fields

Product Request

Personal Info

* Required Fields